Xuguang Zheng
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
36
Citations
2,206
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1997
Xuguang Zheng's research is associated with topics in biochemistry and molecular biology, including cancer-related mechanisms (such as MicroRNA regulation, HER2/EGFR signaling, and tumor hypoxia/metabolism) and nanomedicine approaches for cancer detection and treatment. One identified publication examined a drug combination therapy for protecting brain tissue after ischemia-reperfusion injury, a condition where blood flow is restored after being blocked, potentially causing tissue damage. The available bibliographic record is limited, so the overall scope of this researcher's work cannot be fully characterized from the provided data.
Publication output over the last decade has been sparse and irregular, with several years showing no recorded output and a low average of 0.6 publications per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Combination of tetrandrine and 3-n-butylphthalide protects against cerebral ischemia-reperfusion injury via ATF2/TLR4 pathway
Immunopharmacology and Immunotoxicology · 2021
- Scientific Reports×1
- Haematologica×1
- Immunopharmacology and Immunotoxicology×1
- Thyroid×1
- bioRxiv (Cold Spring Harbor Laboratory)×1
- Anqi Li
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jia Wang
Biochemistry, Genetics and Molecular Biology · Indiana University
- Andrea L. Kasinski
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Ahmed Mansour
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Anirban Mitra
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile